Using PA-induced HepG2 cells as a model, the effects of PCB2 on ERS and NLRP3 inflammasome were investigated in vitro to provide pharmacological evidence for therapeutic strategies for NAFLD. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.